Drug Discovery and Development
We create molecules that matter in the lives of patients – not just symptom-managing, but disease-modifying innovations. We call this “making hope real.”
Our pipeline reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Swipe
Pipeline - Promising, novel, wholly-owned ADC technology platforms
Our Science
We employ the latest insights in tumor biology and immunology in our search for new molecular targets and development of new mechanisms for antibody-drug conjugates (ADCs) and small molecule programs.
Platforms
Our antibody drug conjugate (ADC) technology platforms are generating potential first and best in class assets, including novel proprietary payloads, linker and drug conjugation and improved targeting. This includes clinically validated MOAs, dual payloads, tumor and site-specific release, optimized antibody scaffolds and increased tumor selectivity. These platforms are enabling us to forge a new pathway in ADC development and oncology treatment.
